Baxter International | BAX - Operating Expenses


Baxter International reported $2.68B in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
Abbott USD 10.46B 1.15B Jun/2026
AngioDynamics USD 81.95M 1.68M Sep/2025
Artivion USD 111.2M 9.45M Dec/2025
AtriCure USD 143.94M 3.22M Jun/2026
Baxter International USD 2.68B 3.36B Jun/2026
Becton, Dickinson and Co. USD 24.42B 283M Jun/2026
Boston Scientific USD 4.2B 49M Jun/2026
Cooper Companies USD 1.11B 301.2M Mar/2026
Dexcom USD 990.1M 53.5M Jun/2026
Edwards Lifesciences USD 1.22B 87.6M Jun/2026
Fresenius EUR 5.23B 9M Jun/2026
Globus Medical USD 835.58M 239.73M Jun/2026
Halozyme Therapeutics USD 193.34M 1.15M Jun/2026
ICU Medical USD 491.25M 8.59M Jun/2026
Inogen USD 49.14M 665K Sep/2024
Insulet USD 672M 32.3M Jun/2026
Integra LifeSciences USD 1.04B 971K Jun/2026
Intuitive Surgical USD 1.91B 3.6M Jun/2026
J&J USD 17.83B 388M Jun/2026
Laboratory Of America USD 3.27B 146.9M Jun/2026
Medtronic USD 7.72B 436M Mar/2026
Merit Medical Systems USD 358.44M 20.72M Jun/2026
Quest Diagnostics USD 2.58B 88M Jun/2026
Smith & Nephew USD 2.59B 71M Jun/2026
Stryker USD 4.8B 118M Jun/2026
Tandem Diabetes Care USD 268.35M 3.7M Jun/2026
Teleflex USD 2.9B 179.9M Jun/2026
Terumo JPY 222.33B 46.54B Jun/2026
Zimmer Biomet Holdings USD 1.83B 140.7M Jun/2026